Tuesday, 20 Mar 2018

You are here

DEA Cracks Down on Illicit Fentanyl

Reuters reports that  U.S. Drug Enforcement Administration (DEA) has declaed it would classify illicit versions of fentanyl at the same level as heroin, allowing criminal prosecution of anyone who possesses, distributes or manufactures illicit versions of the drug.

We previously reported on increasing opioid overdose deaths (quadrupled from 1999 to 2015) and that most of these were from heroin and illicitly manufactured fentanyl. (https://buff.ly/2eHAjpn)

According to the U.S. Centers for Disease Control and Prevention, opioids were responsible for more than 33,000 U.S. deaths in 2015. Fentanyl is 50 times more potent than heroin and 100 times more potent than morphine.

Currently fentanyl is currently classified as a Schedule II drug, meaning it is highly addictive but has a medical purpose.

The DEA has now named illicit fentanyl as a Schedule 1 drug, along with heroin, means that is addictive and has no medicinal purpose.

These drugs are chemically similar to fentanyl and have similar effects on the human body, but chemists tweak their molecular structure so that they fall outside of the DEA’s scheduling regime, thereby skirting the law.

The new  emergency scheduling change of fentanyl analogues is only temporary and will last 2 years, but the DEA can either extend it for an additional year or make permanent schedule changes to protect the public.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioid Overdoses Jump 30% in 2017

The CDC released new information yesterday showing that emergency department (ED) visits for opioid overdoses rose 30% in the US from July 2016 through September 2017; in addition, those with an overdose are more likely to a repeat overdose.

The data was presented as part of a new CDC “Vital Signs” report which describes recent trends in healthcare - with this report addressing opioid overdoses using emergency department data.

Opioids No Better than NSAIDs at Chronic Pain

JAMA reports that the SPACE trial demonstrates patients with chronic back or arthritis pain respond equally to 12 months of either opioids or non-opioid (acetaminophen or NSAIDs) analgesics. 

Top 10 MMWR CDC Reports from 2017

Here are the 10 most talked about MMWR Reports of 2017. 

Cannibis Weakly Effective in Neuropathic Pain

The medical use of cannabis is often extended to management of chronic pain and neuropathic pain.

A metanalysis of 27 chronic pain trials show that there is low-strength evidence that cannabis alleviates neuropathic pain but insufficient evidence in other pain populations.

However, there was little evidence that cannabis can alleviate pain associated with multiple sclerosis, cancer, or rheumatic conditions.  

AASM Guidelines for Sleep Apnea Testing

A task force from the American Academy of Sleep Medicine (AASM) performed a systematic review of the scientific literature on obstructive sleep apnea and screening tests.